


Advisory Panel on Rare Disease Biographies



Scott Berns, MD, MPH, FAAP

Chair, Advisory Panel on Rare Disease
Stakeholder Affiliation: Clinicians

Chief Executive Officer, National Institute for
Children's Health Quality

Email: sberns@nichq.org

Term Ends August 2021

Scott Berns is the President and CEO of the National Institute for Children's Health Quality (NICHQ), a nonprofit organization that works to improve children's health, and a co-Founder of The Progeria Research Foundation (PRF), which aims to discover treatments and the cure for Hutchinson-Gilford progeria syndrome and its aging-related conditions.

As Chair of the PRF Board, Berns ensures that PRF is a key force behind the discovery of the progeria gene, and he has developed programs and services to aid both those affected by progeria and the scientists who conduct progeria research. Berns has made multiple media appearances as an expert in perinatal health, and his son Sam and family were featured in an HBO Emmy Award-winning documentary titled *Life According to Sam*.

Berns is a board-certified pediatrician and pediatric emergency physician. He is a Clinical Professor of Pediatrics at the Warren Alpert Medical School of Brown University in Providence, Rhode Island, and a Clinical Professor of Health Services, Policy, and Practice at the Brown School of Public Health. Berns received his bachelor's and medical degrees from Boston University. He completed his residency in pediatrics at Rhode Island Hospital and completed a fellowship in pediatric emergency medicine at Children's National Medical Center in Washington, DC. He earned a Master of Public Health with a concentration in health, policy, and management from the Harvard School of Public Health.

At PCORI's fifth Annual Meeting in September 2019, Berns and his wife Leslie Gordon, MD, PhD, presented the [Opening Keynote](#).



Doug Lindsay, BS

Co-Chair, Advisory Panel on Rare Disease
Stakeholder Affiliation: Patients, Caregivers and
Patient Advocates

Personal Medical Consultant and Founder, Doug
Says LLC.

Email: doug@doug Lindsay.net

Term Ends August 2022

Doug Lindsay became ill at age 21 and spent the next 11 years home- and bedbound until he figured out what was wrong, developed novel treatments to keep his rare autonomic-adrenal condition at bay, and eventually developed the innovative surgery used to treat him.

During Lindsay's 14-year medical odyssey, he worked with 35 senior faculty at 28 institutions, developed new uses for five existing prescription drugs, won a national first court case protecting patients' rights, and developed the concept for the two successful, innovative adrenal surgeries used to treat his case.

Now, Lindsay is a nationally recognized speaker on the role of hope and character in innovation and in life. He is a Community Advisory Board member for Washington University's Institute of Clinical and Translational Sciences and Institute for Public Health. He also provides an in-depth personal medical consultant service to a small number of rare disease and complex condition patients who have found themselves trapped in the medical system.



Sarah Bacon, MS

Member, Advisory Panel on Rare Disease
Stakeholder Affiliation: Patients, Caregivers and
Patient Advocates

Email: sarah.bacon9@gmail.com

Term Ends August 2023

Sarah Bacon is a rare disease patient, advocate, and writer. Shortly after her 2013 diagnosis with lymphangioleiomyomatosis (LAM), and after the sequester cuts to the National Institutes of Health, she wrote an op-ed in The Atlantic, "Medical Research Cuts Have Immediate Health Effects." Since then, she has applied her 15 years of professional communications, advocacy, and issue-related campaign design experience to advancing rare disease research and policy.

Bacon suggested and raised funds for a novel study on the link between LAM and melanoma, which share several biomarkers, including proteins. Melanoma took her father's life and threatened hers. Fortunately, hers was caught early. The study bore meaningful results on the high incidence of melanoma family histories in LAM patients. When the LAM Lab faced losing a commitment from Novartis of a \$200,000 in-kind donation for a pilot trial, Bacon advocated with

	<p>Novartis executives and restored the donation.</p> <p>Bacon secured bipartisan sponsors of The OPEN Act in the House of Representatives with Rare Disease Legislative Advocates, spoke on patient-driven medicine for Global Genes and The Milken Institute, and served on Global Genes' grant application review committee. She has written on rare diseases for The Atlantic, Fast Company, The Washington Post, and New York Magazine, and is currently working on her first book, Living with Zebras.</p>
 <p>Roxanna Bendixen, PhD, OTR/L, FAOTA</p> <p>Member, Advisory Panel on Rare Disease Stakeholder Affiliation: Researchers</p> <p>Rehabilitation Scientist, Associate Professor, and Program Director, Department of Occupational Therapy at the University of Pittsburgh</p> <p><u>Email: bendixen@pitt.edu</u></p> <p><i>Terms Ends August 2021</i></p>	<p>Roxanna Bendixen is a Rehabilitation Scientist and Associate Professor at the University of Pittsburgh, Department of Occupational Therapy, School of Health and Rehabilitation Sciences. She also holds a secondary appointment in the Department of Neurology at the University of Pittsburgh. Dr. Bendixen's clinical expertise is in the area of pediatrics and early-onset neuromuscular disorders. Her principal responsibilities at the University of Pittsburgh are in research and teaching. Her current primary research interests include infants and children with early onset neuromuscular disorders; participation and quality of life; validity and reliability of pediatric sleep outcome measures in neuromuscular disorders; and community-based activity monitoring through mobile tracking devices. Her secondary line of research focuses on research engagement with healthcare, community, family, and policy stakeholders to develop organization-level interventions in support of individuals with Intellection and Developmental Disability.</p> <p>Bendixen has served on numerous rare-disease work groups, such as the American Academy of Neurology Muscular Dystrophy Measure Development Work Group and has provided expert scientific review for clinical guidelines in both Duchenne muscular dystrophy and congenital muscular dystrophies. She is a clinical evaluator, scientific reviewer, and member of the Cooperative International Neuromuscular Research Group. Bendixen is a graduate of the</p>

	University of Florida, receiving her bachelor's and master's degrees in Occupational Therapy and her Doctorate in Rehabilitation Sciences.
 <p>Vanessa Boulanger, MSc</p> <p>Member, Advisory Panel on Rare Disease Stakeholder Affiliation: Patients, Caregivers and Patient Advocates</p> <p>Director of Research Programs, National Organization for Rare Disorders</p> <p><u>Email: vboulanger@rarediseases.org</u></p> <p><i>Terms Ends August 2021</i></p>	<p>Vanessa Boulanger is the Director of Research at the National Organization for Rare Disorders (NORD). In this role, she leads the strategic development, growth, and implementation of NORD's research and scientific activities. Prior to joining NORD, Boulanger held leadership positions at the Dana-Farber Cancer Institute in the Center for Community-Based Research, the François-Xavier Bagnoud (FXB) Center for Health and Human Rights, and the Harvard T.H. Chan School of Public Health, in addition to a faculty position at Regis College.</p> <p>Boulanger brings over 15 years of experience addressing health and social inequalities from a range of health and development perspectives to her role at NORD. She holds an MSc degree in Global Health and Population from Harvard University and a BA in International Development and Social Change from Clark University. In 2018, Boulanger was appointed to a three-year term as a member of the Patient-Centered Outcomes Research Institute (PCORI) Advisory Panel on Rare Disease.</p>
 <p>Danielle Boyce, MPH</p> <p>Member, Advisory Panel on Rare Disease Stakeholder Affiliation: Patients, Caregivers, and Patient Advocates</p>	<p>Danielle Boyce is an award-winning rare epilepsy advocate, researcher, public speaker, and writer. Her work has appeared in dozens of scientific journals and her children's book, Charlie's Teacher, is used in children's hospitals nationwide. She has served on several patient and caregiver advisory panels for academic institutions, pharmaceutical companies, nonprofits, the Food and Drug Administration, and PCORI. Boyce formerly worked as Director of Research Technology at the National Organization for Rare Disorders (NORD). She currently holds a position at the Johns Hopkins School of Nursing's Office for Science and Innovation. She has a master's in public health with a concentration in epidemiology and is</p>

<p>Johns Hopkins School of Nursing, Office for Science and Innovation</p> <p><u>Email: dboyce3@jhu.edu</u></p> <p><i>Term Ends August 2023</i></p>	<p>finishing her doctorate in public administration in 2021.</p> <p>After representing the caregiver voice on a PCORI-funded study, Boyce realized that serving on a PCORI advisory panel is the perfect marriage of her research and advocacy skills and is excited to serve patients through her continued involvement with PCORI. She lives outside of Philadelphia with her husband, Jim, and their four children, including Charlie, who has Lennox-Gastaut Syndrome.</p>
 <p>Mathew Edick, PhD</p> <p>Member, Advisory Panel on Rare Disease Stakeholder Affiliation: Patients, Caregivers and Patient Advocates</p> <p>Director of the Center for Strategic Health Partnerships, Michigan Public Health Institute</p> <p><u>Email: mjedick@mphi.org</u></p> <p><i>Term Ends August 2023</i></p>	<p>Mathew J. Edick is the Director of the Center for Strategic Health Partnerships at Michigan Public Health Institute. He is an organizational PCORI Ambassador and has been a principal investigator, co-investigator, project manager, and programmatic/technical assistance lead on four PCORI-funded projects. Edick works with local, regional, and national-scale projects that engage diverse stakeholders to identify and implement innovative solutions for improving health outcomes. He received his doctorate in pharmacogenomics from the University of Tennessee.</p>



Julie Gortze, RN

Member, Advisory Panel on Rare Disease
Stakeholder Affiliation: Patients, Caregivers and
Patient Advocates

Founder, Rare New England

Email: julie@rarenewengland.org

Term Ends August 2021

Julie Gortze is a registered nurse and Founder of Rare New England, a nonprofit patient advocacy organization focused on improving the lives of those living and working with rare and complex disorders. She is helping to create a rare-disease advisory council initiative that is forming through Connecticut legislation, and she is active on a similar bill in Massachusetts that would allow a group of rare-disease stakeholders to form a council to investigate issues in the rare-disease community and find solutions.

Through Rare New England, Gortze is a member of the Regional Genetics Network Steering Committee, Global Genes Alliance, and North Attleboro Commission on Disability. She is a 2017 Health Resources and Services Administration Regional Genetics Collaborative Advocate Leaders Partnership Program Recipient. She has been on various conference planning committees, including the New England Regional Genetics Group and Mito Hope and Help, and has helped organize Rare Disease Day State House events.

Gortze has personal experience with a complex disease and has learned firsthand the barriers patients and families must overcome while searching for a cause for symptoms. As a nurse, she also understands that most medical personnel do not have the familiarity to recognize, diagnose, and treat complex medical disorders, so they need help and support as well.



Salman Hussain is a life sciences consultant at Charles River Associates (CRA), and a member of the Board of Directors for the National Alopecia Areata Foundation (NAAF). He has more than seven years of experience in healthcare research and has advised leading pharmaceutical and biotechnology companies across many therapeutic areas (with a specific focus in rare disease), both globally and in the United States.

Prior to joining CRA, Hussain conducted research at Massachusetts General Hospital and The Dartmouth Institute for Health Policy & Clinical

<p style="text-align: center;">Salman Hussain, MPH</p> <p style="text-align: center;">Member, Advisory Panel on Rare Disease Stakeholder Affiliation: Industry</p> <p style="text-align: center;">Consultant, Charles River Associates</p> <p style="text-align: center;"><u>Email: mister.salmanhussain@gmail.com</u></p> <p style="text-align: center;"><i>Term Ends August 2023</i></p>	<p>Practice, specializing in the rare disease alopecia areata universalis and the interface between dermatology and mental health. While working with NAAF on a PCORI-funded project, he developed a patient-centered outcomes research and comparative clinical effectiveness research training program for patients. He was so inspired after this project that he became a PCORI Ambassador and has continued to advise his pharmaceutical clients and academic researchers on how they can meaningfully engage with patients to inform their research.</p> <p>In addition to his work in alopecia areata, Hussain has advised and conducted substantial research for pharmaceutical companies to better understand the patient experience in many rare diseases, such as Duchene muscular dystrophy, spinal muscular atrophy types 3 and 4, acute lymphoblastic leukemia, maple syrup urine disease, nemaline myopathy, GM3-synthase deficiency, aromatic 1-amino acid decarboxylase deficiency, and acute hepatic porphyria</p>
<div data-bbox="344 1075 649 1440" data-label="Image"> </div> <p style="text-align: center;">Tilicia Mayo-Gamble, PhD, MPH, MA</p> <p style="text-align: center;">Member, Advisory Panel on Rare Disease Stakeholder Affiliation: Patients, Caregivers and Patient Advocates</p> <p style="text-align: center;">Assistant Professor, Georgia Southern University</p> <p style="text-align: center;"><u>Email: dr.mayogamble@gmail.com</u></p> <p style="text-align: center;"><i>Term Ends August 2021</i></p>	<p>Tilicia Mayo-Gamble is an Assistant Professor for the Department of Health Policy and Community Health in the Jiann-Ping Hsu College of Public Health at Georgia Southern University. She conducts research on community-engaged approaches to improving protective health behaviors in patients with one or more chronic conditions. In her home life, Dr. Mayo-Gamble is the spouse to a husband with sickle cell disease. Much of her research interests are guided by her and her husband's experiences interacting with healthcare providers on sickle cell disease management and challenges with managing the disease at home. She recognizes that books and online text do not address her husband's needs—this information can be gained only through lived experience. She also understands the difficulties of providing input to healthcare providers and researchers about personal health.</p> <p>Dr. Mayo-Gamble became an advisory panel member to share the voices of individuals with sickle cell disease. She sees this as a unique</p>

	<p>opportunity to bring patient and caregiver perspectives into the discourse.</p>
<div data-bbox="344 279 667 644" data-label="Image"> </div> <p data-bbox="402 682 602 711">Nancy Rose, MD</p> <p data-bbox="256 753 747 819">Member, Advisory Panel on Rare Disease Stakeholder Affiliation: Clinicians</p> <p data-bbox="212 861 789 926">Adjunct Professor of Obstetrics and Gynecology, University of Utah</p> <p data-bbox="324 968 677 997"><u>Email: ncrose922@gmail.com</u></p> <p data-bbox="360 1039 639 1068"><i>Term Ends August 2023</i></p>	<p>Currently a Medical Consultant at the National Coordinating Center for the Regional Genetics Networks, Nancy Rose was previously the Director of Reproductive Genetics at Intermountain Healthcare in Salt Lake City Utah for 16 years, with the goal to decrease healthcare disparities and disseminate information prior to and during pregnancy as well as in the newborn period throughout the state. She has served as the President of the American Board of Medical Genetics and Genomics and Chair of the Committee on Genetics for the American College of Obstetricians and Gynecologists and continues to serve on committees for the American College of Medical Genetics and Genomics, the American College of Obstetricians and Gynecologists, the American Board of Medical Genetics and Genomics, and the American Board of Medical Specialties. Rose remains an adjunct Professor of Obstetrics and Gynecology at the University of Utah.</p>
<div data-bbox="336 1115 667 1434" data-label="Image"> </div> <p data-bbox="332 1472 670 1501">Sherene Shalhub, MD, MPH</p> <p data-bbox="256 1543 747 1608">Member, Advisory Panel on Rare Disease Stakeholder Affiliation: Clinicians</p> <p data-bbox="209 1650 792 1753">Vascular Surgeon and Translational Researcher; Director of the Vascular Genetic Clinic, University of Washington</p> <p data-bbox="355 1795 646 1824"><u>Email: shalhub@uw.edu</u></p> <p data-bbox="360 1866 639 1896"><i>Term Ends August 2023</i></p>	<p>Sherene Shalhub is a vascular surgeon and translational researcher at the University of Washington (UW) and the Director of its Multidisciplinary Vascular Genetics Clinic. She is a former NIH T32 Postdoctoral Fellow and recently completed the two-year Rising Star Program at the Clinical and Translation Science Awards (CTSA)-funded UW Institute of Translational Health Sciences. Her work aims to provide high-quality care to patients suffering from rare vascular conditions and to improve the success of surgical repair and long-term survival for these high-risk patients.</p>



Saira Sultan, JD

Member, Advisory Panel on Rare Disease
Stakeholder Affiliation: Policy Makers

CEO, Connect4Strategies

Email: saira.sultan@connect4strategies.com

Term Ends August 2021

Saira Sultan, JD, has been at the nexus of patient groups, the medical community, drug/device manufacturers, and governmental organizations, for more than two decades. Her passion for rare and ultrarare disease issues culminated in her founding of the Haystack Project in 2016. Through Haystack, Sultan has given voice to the experiences and perspectives of patients with rare and ultrarare conditions to influence research and policy making. She also continues to work with patient groups suffering from more common conditions such as cancer, sickle cell disease, pain, and addiction as the President and CEO of Connect 4 Strategies, a boutique reimbursement, value, and access consulting firm.

Her history with the cancer community stretches back nearly 20 years to when she directed government affairs for the Association of Community Cancer Centers. During her career, she also held leadership positions with Pfizer, Sanofi, and Medtronic. Sultan holds a juris doctor from the University of Virginia in Charlottesville, Virginia.



Laura Tosi, MD

Member, Advisory Panel on Rare Disease
Stakeholder Affiliation: Clinicians

Founder and Director of the Bone Health
Program, Children's National Hospital

Laura L. Tosi serves on the Board of Directors of the Osteogenesis Imperfecta Foundation (OIF) and the US Bone & Joint Initiative. She serves as site principal investigator for the Brittle Bone Disease Consortium's Osteogenesis Imperfecta Longitudinal Study and has particularly supported the study's patient-reported outcomes research. Tosi served as the principal investigator for the OIF's first patient centered outcomes research project and is currently serving as a co-lead for an OIF PCORI-funded project on improving patient-centered outcomes. She is chair of the Rare Bone Disease Alliance Steering Committee and faculty chair of the Rare Bone Disease TeleECHO program.

Tosi is the Founder and Director of the Bone Health Program at Children's National Hospital and Associate Professor of orthopaedics and pediatrics at George Washington University in Washington, D.C. Her clinical practice focuses on

<p><u>Email: ltosi@childrensnational.org</u></p> <p><i>Term Ends August 2023</i></p>	<p>the orthopedic care of children and young adults with physical disabilities and/or issues related to bone health/rare skeletal disease. She is a graduate of Harvard Medical School and received her orthopaedic training at the Columbia Presbyterian Hospital in New York and the Hospital for Sick Children in Toronto.</p>
<div data-bbox="331 495 675 869" data-label="Image"> </div> <p>Naomi Aronson, PhD</p> <p>Ex-Officio Member from PCORI's Methodology Committee</p> <p>Executive Director, Clinical Evaluation, Innovation, and Policy, Blue Cross Blue Shield Association (BCBSA)</p> <p><u>Email: naomi.aronson@bcbsa.com</u></p>	<p>Dr. Naomi Aronson leads BCBSA clinical effectiveness and policy engagement with government, regulatory agencies, and policy consortia. Her areas of leadership include comparative effectiveness, patient centered research, safety surveillance, regulatory science, and methodological standards. Previously, Dr. Aronson led the development of the BCBSA Technology Evaluation Center (TEC), now Evidence Street™ (ES), as a nationally recognized technology assessment program and an Evidence- based Practice Center (EPC) of the Agency for Healthcare Research and Quality (AHRQ).</p> <p>She is a member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), the Health Technology Assessment International Health Policy Forum, the National Academy of Medicine Genomics Roundtable, the New Drug Development Paradigms (NEWDIGS) initiative of the MIT Center for Biomedical Innovation, and the Medical Device Innovation Consortium (MDIC) National Evaluation System for Health Technology (NEST) Governing Committee.</p> <p>Prior to joining BCBSA, Dr. Aronson was a member of the Northwestern University faculty, specializing in the sociology of science and medicine. She also was a post-doctoral fellow in the Science, Technology and Society Program at the Massachusetts Institute of Technology.</p>

RDAP Winter 2020 Meeting Presenters & Support Staff



Karen Martin, MIA
Program Director, Engagement Awards
Email: kmartin@pcori.org



Fatou Ceesay, MPH
Program Officer, Engagement Awards
Email: fceesay@pcori.org



Ivey Wohlfeld, BA
Program Manager, Engagement Awards
Email: iwohlfeld@pcori.org



Elisabeth Houtsmuller, PhD
Associate Director, Healthcare Delivery and
Disparities Research
Email: ehoutsmuller@pcori.org



Kelly Dunham, MPP

Senior Manager, Strategic Initiatives, Office of the
Chief Science Officer

Email: kdunham@pcori.org



Laura Lyman Rodriguez, PhD

Interim Chief Program Support Officer, Senior
Advisor to the Executive Director

Email: llrodriguez@gmail.com



Jean Slutsky, PA, MSPH

Chief Engagement and Dissemination Officer

Email: jslutsky@pcori.org



Katherine Jackstadt, MS

Program Officer, Office of the Executive Director

Email: kjackstadt@pcori.org

PCORI Rare Disease Advisory Panel Team



Carly Paterson Khan, PhD, MPH, RN
Program Officer, Healthcare Delivery and
Disparities Research

Email: ckhan@pcori.org



Nora McGhee, PhD
Senior Program Officer, Clinical Effectiveness and
Decision Science

Email: nmcghee@pcori.org



Rohini Mohanraj, MHA
Program Associate, Research Infrastructure

Email: rmohanraj@pcori.org